Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy for Residual Cervical Cancer After CCRT
NCT04409860Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of paclitaxel and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started May 2020; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04409860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409860.